BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2681441)

  • 1. ras mutations in human leukemia and related disorders.
    Greenberger JS
    Int J Cell Cloning; 1989 Nov; 7(6):343-59. PubMed ID: 2681441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of ras gene mutations and methylation state in human leukemias.
    Browett PJ; Norton JD
    Oncogene; 1989 Aug; 4(8):1029-36. PubMed ID: 2668844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
    Spandidos DA
    Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
    Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
    Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of N-ras induced by ultraviolet irradiation in vitro.
    Van der Lubbe JL; Rosdorff HJ; Bos JL; Van der Eb AJ
    Oncogene Res; 1988; 3(1):9-20. PubMed ID: 3060800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
    Gallagher AP; Burnett AK; Bowen DT; Darley RL
    Cancer Res; 1998 May; 58(9):2029-35. PubMed ID: 9581849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia].
    Hirai H; Hirano N; Yazaki Y
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1090-7. PubMed ID: 2053767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation.
    Shen S; Passioura T; Symonds G; Dolnikov A
    Exp Hematol; 2007 Jun; 35(6):908-19. PubMed ID: 17533045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents.
    Pedersen-Bjergaard J; Janssen WG; Lyons J; Philip P; Bartram CR
    Cancer Res; 1988 Apr; 48(7):1812-7. PubMed ID: 3280121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oncogene activation in the leukemias].
    Moroni C
    Schweiz Med Wochenschr; 1984 Oct; 114(40):1369-73. PubMed ID: 6593822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The involvement of oncogenes and suppressor genes in human neoplasia.
    Brodeur GM
    Adv Pediatr; 1987; 34():1-44. PubMed ID: 3318293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of normal and mutant ras proteins in human acute leukemia.
    Shen WP; Aldrich TH; Venta-Perez G; Franza BR; Furth ME
    Oncogene; 1987 May; 1(2):157-65. PubMed ID: 3325880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point mutations in both transforming and non-transforming codons of the N-ras proto-oncogene of Ph+ leukemias.
    Rovera G; Reichard BA; Hudson S; Bittenbender S; Yamada M; Tournay O; Preisler HD
    Oncogene; 1989 Jul; 4(7):867-72. PubMed ID: 2666907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oncogenes in human leukemia].
    Takaku F
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):617-23. PubMed ID: 2650633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
    Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
    Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.
    Hirai H; Kobayashi Y; Mano H; Hagiwara K; Maru Y; Omine M; Mizoguchi H; Nishida J; Takaku F
    Nature; 1987 Jun 4-10; 327(6121):430-2. PubMed ID: 3295562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
    Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
    J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.